← Back to News

Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)

positiveAnalyst ratingMulti dayYahoo Finance ·1 Jun 2026Original article ↗
Oraklio AI Analysis

Analyst initiation can drive near-term sentiment and trading activity for the specific stock, though the rating is not explicitly bullish (Peer Perform) and no price target was provided.

Article

Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA) Fatima Gulzar Mon, June 1, 2026 at 10:03 AM GMT+2 1 min read TYRA ^RUT Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the 10 Best Russell 2000 Stocks to Invest In According to Hedge Funds .

On May 19, Wolfe Research initiated Tyra Biosciences, Inc. (NASDAQ:TYRA) with a Peer Perform rating and no price target. The analyst stated dabogratinib could “achieve the CR bar for LR IR NMIBC” while remaining “on the fence” pending safety de-risking.

On May 13, Tyra Biosciences, Inc. (NASDAQ:TYRA) reported Q1 results, advancing its “dabogratinib 3×3” strategy, dosing the first LG-UTUC patient in SURF303, and targeting initial results in 2027. Cash stood at $383.

5 million, funding operations into 2H 2028. The company posted a net loss of $39. 3 million from $28.

1 million a year earlier and raised R&D expenses to $33. 5 million. Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc.

(TYRA) Photo by National Cancer Institute on Unsplash CEO Todd Harris said the firm “continues to advance with steady progress,” flagging multiple data readouts in 2026. Chief Medical Officer Doug Warner noted dabogratinib may “represent a meaningful shift” in treatment, pointing to the Phase 2 studies across three indications. Tyra Biosciences, Inc.

(NASDAQ:TYRA) is a precision oncology firm that develops purpose-built treatments to overcome tumor resistance and improve cancer patients’ outcomes. While we acknowledge the potential of TYRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the   best short-term AI stock .

READ NEXT:  33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy .   Disclosure: None. Follow Insider Monkey on Google News .

Oraklio AI Trading Intelligence

News is just the start.

Oraklio turns news, price data, and market signals into structured BUY / SELL / NO_TRADE calls - updated continuously throughout the trading day.

Get started free

Already have an account? Sign in →